{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-112341","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.708420+00:00","generated_at":"2026-05-17T09:07:57.341530+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FibroGen completes $220M sale of China ops to AstraZeneca; cash runway extended to 2028","bullets":["Total consideration ~$220M ($85M enterprise value + ~$135M net cash), $60M above initial guidance.","Repaid ~$81M term loan to Morgan Stanley Tactical Value; cash runway now extended into 2028.","Phase 2 monotherapy trial of FG-3246 in mCRPC on track to commence in Q3 2025.","Phase 3 protocol for roxadustat in LR-MDS anemia to be submitted in Q4 2025 after positive FDA meeting.","FibroGen retains roxadustat rights in U.S. and all markets not licensed to Astellas (excl. China/South Korea)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-112341","json":"https://secwatch.observer/filing/0000950170-25-112341.json","markdown":"https://secwatch.observer/filing/0000950170-25-112341.md","text":"https://secwatch.observer/filing/0000950170-25-112341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017025112341/0000950170-25-112341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017025112341/fgen-20250829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:07:57.341530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}